Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Meloxicam
Drug ID BADD_D01374
Description Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.[A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Indications and Usage Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above.[L11398] Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. [A190189] Meloxicam, together with the local anesthetic [bupivacaine], is indicated for the production of postsurgical analgesia in adult patients for up to 72 hours following bunionectomy, open inguinal herniorrhaphy or total knee arthroplasty.[L34100]
Marketing Status approved; vet_approved
ATC Code M01AC06
DrugBank ID DB00814
KEGG ID D00969
MeSH ID D000077239
PubChem ID 54677470
TTD Drug ID D0G7FJ
NDC Product Code 72919-124; 80425-0041; 38779-2746; 53069-0790; 69237-004; 43602-623; 50090-5339; 51655-571; 55289-272; 63629-2019; 68788-1701; 70518-0171; 70518-0200; 70934-011; 70954-077; 71610-657; 71740-339; 51869-0007; 53747-006; 60592-994; 50268-526; 51655-731; 53002-2537; 60760-404; 61442-127; 63187-082; 63187-083; 70518-1630; 71610-516; 0615-8124; 72865-137; 76420-043; 49452-4402; 65862-097; 16571-776; 42708-093; 45865-360; 61442-126; 61919-434; 64380-715; 65841-050; 65841-051; 67296-1317; 67296-1460; 68071-2184; 68180-189; 68180-502; 68382-050; 68788-9418; 70518-1299; 71205-923; 71335-0406; 58118-1158; 60687-199; 60760-448; 60760-653; 67296-0823; 68788-7904; 69097-158; 70934-010; 71335-1956; 80425-0044; 51552-1377; 51869-0008; 58624-0430; 59349-0003; 70859-007; 42708-007; 51655-577; 63629-3328; 64380-716; 80425-0043; 53104-7574; 65862-098; 43063-395; 43353-979; 61919-469; 67296-1817; 68071-1919; 68180-501; 68462-140; 70518-2631; 71610-542; 0615-8040; 76282-152; 80425-0042; 80425-0083; 22365-116; 52119-003; 56125-750; 68225-112; 16571-777; 49999-869; 68382-051; 68462-141; 70518-3023; 71205-924; 71610-583; 76420-039; 17373-1157; 17373-1158; 35356-808; 43063-396; 43602-624; 51407-611; 53002-2535; 60760-419; 63629-3248; 68071-3030; 68071-4987; 68788-7726; 70954-076; 71335-1888; 71610-580; 80425-0045; 65862-223; 68981-032; 51655-177; 67296-0583; 68180-188; 71335-1618; 71610-544; 51927-0032; 43063-401; 50268-525; 67296-1250; 69097-159; 70518-1828; 71335-2080; 72865-138; 76282-153; 29300-124; 29300-125; 50090-0985; 50090-5861; 51407-610
UNII VG2QF83CGL
Synonyms Meloxicam | Miloxicam | Parocin | Mobic | Mobicox | Mobec | Masflex | Movicox | Reumoxicam | Uticox | Movalis
Chemical Information
Molecular Formula C14H13N3O4S2
CAS Registry Number 71125-38-7
SMILES CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diverticulum07.10.01.0010.000016%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000179%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000024%Not Available
Drug ineffective08.06.01.0060.000496%Not Available
Drug interaction08.06.03.0010.000032%Not Available
Dry mouth07.06.01.002--
Duodenal ulcer07.04.02.0020.000098%
Duodenal ulcer haemorrhage07.04.02.004; 24.07.02.0200.000040%Not Available
Duodenal ulcer perforation07.04.02.003--Not Available
Dysarthria19.19.03.001; 17.02.08.0010.000035%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000051%
Dyspnoea22.02.01.004; 02.11.05.003--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000024%Not Available
Eosinophilia01.02.04.0010.000032%
Eructation07.01.02.003--
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.0060.000032%
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Faeces discoloured07.01.03.0020.000048%Not Available
Fall12.01.08.002--
Fatigue08.01.01.0020.000246%
Feeling abnormal08.01.09.0140.000089%Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.0020.000035%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000016%
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.000059%
Gamma-glutamyltransferase increased13.03.04.024--
Gastric haemorrhage24.07.02.007; 07.12.01.0010.000284%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages